The new approaches were extensively reviewed in 2021 and 2022 but rely intensely on state and location-distinct dynamic products for reduced and middle-revenue international locations that experienced main COVID-similar disruptions to TB diagnosis and remedy, in the absence of reputable immediate measurements of condition stress from national illness surveillance programs https://hc6.org/